Cardiology
Lorundrostat Lowers 24‑Hour Systolic Blood Pressure in Treatment‑Resistant Hypertension but Raises Hyperkalemia Concerns
A randomized, placebo‑controlled trial found lorundrostat reduced 24‑hour systolic BP by ~7–8 mm Hg versus placebo in patients with uncontrolled, treatment‑resistant hypertension; notable rates of marked hyperkalemia occurred only in active
